Standout Papers

Dapagliflozin in Patient... 2003 2026 2010 2018 2.8k
  1. Dapagliflozin in Patients with Chronic Kidney Disease (2020)
    Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. New England Journal of Medicine
  2. Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes (2007)
    Andrew S. Levey, R. C. Atkins et al. Kidney International
  3. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019)
    Brendon L. Neuen, T. Kue Young et al. The Lancet Diabetes & Endocrinology
  4. NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1 (2003)
    Jaime A. Davidson, Alan Wilkinson et al. Transplantation
  5. Effects of Phosphate Binders in Moderate CKD (2012)
    Geoffrey A. Block, David C. Wheeler et al. Journal of the American Society of Nephrology
  6. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference (2015)
    Arlene B. Chapman, Olivier Devuyst et al. Kidney International
  7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial (2020)
    David C. Wheeler, Bergur V. Stefánsson et al. The Lancet Diabetes & Endocrinology
  8. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis (2018)
    Iain C. Macdougall, Claire White et al. New England Journal of Medicine
  9. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021)
    David C. Wheeler, Robert D. Toto et al. Kidney International

Immediate Impact

105 standout
Sub-graph 1 of 17

Citing Papers

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024 Standout
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
2023 Standout
7 intermediate papers

Works of David C. Wheeler being referenced

Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study
2010
and 4 more

Author Peers

Author Last Decade Papers Cites
David C. Wheeler 6497 5895 3792 266 15.3k
Michael W. Steffes 5434 7005 4163 149 19.2k
Fan Fan Hou 4655 3854 1966 297 12.6k
Katherine R. Tuttle 7164 7969 3409 291 18.4k
Robert D. Toto 8749 5657 3460 248 20.5k
Lawrence G. Hunsicker 8340 5286 3001 132 18.6k
Rijk O. B. Gans 2952 3672 2123 358 14.9k
Ian H. de Boer 7536 6240 2979 318 19.3k
Thomas H. Hostetter 10470 2872 2159 182 19.5k
Sankar D. Navaneethan 4502 2995 4682 217 12.8k
Hans‐Henrik Parving 7273 8667 2177 231 20.2k

All Works

Loading papers...

Rankless by CCL
2026